Blood transfusion reactions and transplant rejection: Pathology review

3,518views

Blood transfusion reactions and transplant rejection: Pathology review

Internal Medicine

Internal Medicine

Blood transfusion reactions and transplant rejection: Pathology review
Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Non-corticosteroid immunosuppressants and immunotherapies
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Neuroendocrine tumors of the gastrointestinal system: Pathology review
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Water-soluble vitamin deficiency and toxicity: B1-B7: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
HIV and AIDS: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Environmental and chemical toxicities: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Dementia and delirium: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Non-biologic disease modifying anti-rheumatic drugs (DMARDs)
Osteoporosis medications

Questions

USMLE® Step 1 style questions USMLE

0 of 10 complete

Start
A 50-year-old individual presents to the physician for evaluation of persistent diarrhea and a skin rash for the past week. The patient’s diarrhea began one week ago, is watery, and persists even during fasting. Yesterday, the patient noticed blood in the stool as well. In addition, the patient started experiencing a painful rash on their neck, shoulders, and the palms of their hands. The patient was diagnosed with acute leukemia six months ago and received a bone marrow transplantation two months ago after chemotherapy and radiotherapy. Vitals are within normal limits. On physical examination, a maculopapular rash is noted on the shoulders, arms, palms, and soles. Oral examination reveals the presence of mouth ulcers. On laboratory tests, serum alkaline phosphatase and serum bilirubin are elevated. Which of the following is the most likely cause of this patient’s condition?  

Transcript

Watch video only

35 year old Adam is brought to the emergency department by an ambulance after being involved in a motor vehicle crash. Upon examination, you notice that he is significantly bleeding from his thigh, so you decide to give him a blood transfusion. Five minutes later, he develops shortness of breath, one episode of nonbloody vomiting, and a diffuse rash with erythematous borders starts to appear all over his body. Also, his blood pressure drops to 60 over 40 millimeters of mercury. Some days later, you see 50 year old Jack, who’s complaining of fever, malaise, and a decreased production of urine for the past two days. On further questioning, Jack tells you that he underwent a kidney transplantation one month ago. Upon examination, you realize that he has a high blood pressure of 150 over 80 millimeters of mercury. You decide to perform a biopsy of his transplanted kidney, which reveals a dense lymphocytic infiltrate.

Okay, based on the initial presentation, Adam seems to have some form of blood transfusion reaction, which includes any adverse event that occurs following blood transfusion. Jack, on the other hand, seems to be experiencing some form of transplant rejection, which is when the immune system of the recipient attacks the transplanted organ or graft.

All right, let’s start with blood transfusion reactions. For your tests, there are six blood transfusion reactions that you need to be aware of, including anaphylactic or allergic transfusion reaction, acute hemolytic transfusion reaction, delayed hemolytic transfusion reaction, febrile nonhemolytic transfusion reaction, transfusion-related acute lung injury, and transfusion-associated circulatory overload.

Let’s begin with the anaphylactic or allergic transfusion reaction. It is a type I hypersensitivity reaction mediated by the recipient’s IgE antibodies against plasma proteins like immunoglobulins found in transfused blood. Initially, the proteins in the donor’s plasma will be recognized by preformed IgE immunoglobulins present on the surface of mast cells, which in turn release their granules containing inflammatory mediators, such as histamine.

As a result, within seconds or minutes of starting the transfusion, the recipient develops urticaria, which is a raised pale rash with erythematous borders, accompanied by pruritus or itching and fever, as well as wheezing or a whistling sound in the chest, hypotension or low blood pressure, which can potentially progress into respiratory arrest, meaning the individual may stop breathing, as well as anaphylactic shock, which is when the blood pressure is too low to maintain adequate tissue perfusion. Sometimes though, symptoms start 2 to 3 hours after the transfusion, as more time is needed for the mature plasma cells to be formed and produce IgE antibodies in response to the foreign plasma proteins.

What you definitely need to know for your exams is that anaphylactic transfusion reaction commonly occurs in individuals with IgA deficiency, because they have anti-IgA antibodies, and IgA is found in most blood products. So, bear in mind that individuals with IgA deficiency should receive washed blood products from which IgA immunoglobulins have been removed.

Next is acute hemolytic transfusion reaction, which is a type II hypersensitivity reaction where the recipient’s preformed antibodies attack the transfused red blood cells. This transfusion reaction typically occurs because of an ABO blood type incompatibility.

Now, the ABO system refers to the type of glycoproteins found on the surface of red blood cells; so you can have either type A, type B, type AB, or neither, which is called type O blood. The immune system produces antibodies against the glycoproteins that you don’t have. People with type A blood have antibodies against type B glycoproteins and vice versa, while those with type AB blood don’t have antibodies against any red blood cell glycoprotein, and finally, people with type O blood have antibodies to both A and B glycoproteins.

Now, as an example, if a recipient with type A blood is given a transfusion from a donor with type B blood, the recipient’s immune system will attack the donor blood, leading to intravascular hemolysis or red blood cell destruction within the recipient’s blood vessels.

Symptoms of acute hemolytic transfusion reaction can begin during the transfusion due to the presence of preformed antibodies, or anytime within 24 hours from the transfusion, which is the time it takes plasma cells to form the antibodies.

Individuals who have acute hemolytic transfusion reactions may experience fever, hypotension, tachycardia, and tachypnea.

Now, acute hemolysis results in a massive release of hemoglobin into the blood. Some of this hemoglobin breaks up into heme and globin. Heme is then converted into bilirubin, leading to hyperbilirubinemia or high bilirubin in blood. As a consequence, individuals may present with jaundice, which is when the excess bilirubin deposits in the skin and eyes, causing them to turn yellow. On the other hand, some hemoglobin can reach the kidneys to be excreted in the urine, which is known as hemoglobinuria. As a result, individuals with acute hemolytic transfusion reaction may present with red urine associated with flank pain. In addition, free hemoglobin is toxic to the kidneys and can cause acute renal failure.

Now, there’s also delayed hemolytic transfusion reaction, which is when hemolysis starts after 24 hours of transfusion, generally within one to two weeks. This typically occurs when there are antibodies against minor antigens on the donor blood, such as Rhesus or Rh. Now, people are either Rh positive, meaning they have the Rh protein on their red blood cells, or they are Rh negative, meaning it’s absent. So, if an Rh negative person receives Rh positive blood, they could develop a delayed hemolytic transfusion reaction.

Now, keep in mind that this reaction results from an anamnestic response, meaning that to develop a response, the recipient must be previously exposed to these minor antigens, like by a prior transfusion or pregnancy, which led to the development of antibodies without causing a noticeable reaction. On subsequent exposure, like a later blood transfusion or a second pregnancy, these antibodies will be ready to trigger an intense immune reaction.

Now, in delayed hemolytic transfusion reactions, the antibodies don’t directly destroy the donor’s red blood cells, but rather mark them for destruction by organs of the reticuloendothelial system, meaning the spleen and liver, resulting in extravascular hemolysis. Individuals with delayed hemolytic transfusion reactions are often asymptomatic, while some may experience self-limited symptoms, such as a mild fever and jaundice.

All right, next up is febrile nonhemolytic transfusion reaction, which is more common in children for unclear reasons. Now, as the name implies, this reaction doesn’t cause red blood cell destruction, and it mainly manifests as a fever following blood transfusion. This occurs due to the release of inflammatory mediators like cytokines from white blood cells in donor blood.

Another proposed mechanism for febrile nonhemolytic transfusion reaction involves a type II hypersensitivity reaction where antibodies in the recipient’s blood target human leukocyte antigens or HLAs on the surface of the donor's white blood cells. This again causes these cells to break and release their cargo of cytokines into the blood after transfusion. In both cases, the released cytokines put the body in a state of heightened immune response, like when you have a cold.

Symptoms of febrile nonhemolytic transfusion reaction usually start within 1 to 6 hours after transfusion, and include fever, chills, headache, and flushing, which is a sudden reddening that usually involves the face and neck.

Sources

  1. "Robbins & Kumar Basic Pathology. 11th edition. ISBN: 978-0-323-79018-5 " Elsevier (2022)
  2. "Harrison’s Principles of Internal Medicine. 21st edition. ISBN: 978-1-264-26850-4 " McGraw Hill / Medical (2022)
  3. "Transfusion-Related Acute lung injury during liver transplantation: A scoping review. 36(8):2606-2615. " Journal of Cardiothoracic and Vascular Anesthesia (2022)
  4. "Liver transplantation immunology: Immunosuppression, rejection, and immunomodulation. 78(6):1199-1215. " Journal of Hepatology (2023)
  5. "The immunology of organ transplantation. 41(9):543-551. " Surgery (Oxford) (2023)
  6. "Risks of perioperative blood transfusions. 23(2):80-84. " Anaesthesia & Intensive Care Medicine (2022)
  7. "Clinical epigenetics and acute/chronic rejection in solid organ transplantation: An update. 35(2):100609. " Transplantation Reviews (2021)